Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of...
ROCKVILLE, Md., March 29, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the...
View ArticleAkcea Therapeutics Supports World Lipodystrophy Day (Isis Pharmaceuticals Inc)
(Source: Isis Pharmaceuticals Inc) CAMBRIDGE, Mass., March 31, 2016 /PRNewswire/ -- Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals (NASDAQ: IONS) focused on developing and commercializing...
View ArticleRexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of...
(Source: Rexahn Pharmaceuticals Inc) ROCKVILLE, Md., March 29, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next...
View ArticleGlobal Blood Therapeutics Announces Appointment of Jeffrey Farrow as CFO...
(Source: Global Blood Therapeutics Inc) SOUTH SAN FRANCISCO, Calif., April 4, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel...
View ArticleBRIEF-Serodus to evaluate financing options for lead programs
* Says has initiated work to evaluate the company's financing alternatives as part of planning a further development of the lead projects to next development stages - which also goes beyond the end of...
View ArticlePCT SER100 patent application filed - Serodus demonstrates a novel mechanism...
(Source: Serodus ASA) Oslo, April 18, 2016: Serodus ASA (Oslo Axess: SER) has filed a PCT patent application for the Orphan Disease of Pulmonary Hypertension to the United Kingdom patent office. 'We...
View ArticleSerodus enter into Market Making agreement (Serodus ASA)
(Source: Serodus ASA) Oslo, 30. March 2016. Serodus ASA (OAX:SER) Serodus ASA has entered into a market making agreement with Norne Securities AS with effect from 30 March 2016. The purpose...
View ArticleVP Drug Development, Nikolai C. Brun to present at EuroDIA (Serodus ASA)
(Source: Serodus ASA) Oslo, 07. April 2016. Serodus ASA (OAX:SER) announce that VP Drug Development Nikolai C. Brun has been invited to present at EuroDIA; Title: 'Industry Perspective on Today's...
View ArticleNEW CORPORATE PRESENTATION (Serodus ASA)
(Source: Serodus ASA) For more information contact: Tore Kvam CFO, Serodus ASA Mobile: +47 959 34 199 e-mail: tore.kvam@serodus.com Serodus...
View ArticleSerodus to evaluate financing options for lead programs (Serodus ASA)
(Source: Serodus ASA) Oslo, 04. April 2016. Serodus ASA (OAX:SER) today announce that the company has initiated work to evaluate the company's financing alternatives as part of planning a further...
View ArticleGilead paying up to $1.2B for Nimbus unit, drug candidate
Biologic drugmaker Gilead Sciences Inc. said Monday that it will buy a subsidiary of Nimbus Therapeutics LLC and its experimental pill for an increasingly common metabolic disorder that causes...
View ArticleOramed Completes Phase IIb Oral Insulin Study
JERUSALEM, April 5, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery...
View ArticleOramed Completes Phase IIb Oral Insulin Study (Oramed Pharmaceuticals Inc)
(Source: Oramed Pharmaceuticals Inc) JERUSALEM, April 5, 2016 /PRNewswire/ - Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the...
View ArticleMETabolic EXplorer announces the launch of inoLa, a unique, innovative, 100%...
(Source: Metabolic Explorer SA) PR_METEX_INOLA_V1_15 04 2016 METabolic EXplorer announces the launch of inoLaTM, a unique, innovative, 100% natural additive for animal nutrition Clermont-Ferrand, 18...
View ArticleMast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be...
(Source: Mast Therapeutics Inc) SAN DIEGO, April 13, 2016 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle...
View ArticleSynta and Madrigal Announce Merger Agreement to Create Leading...
(Source: Synta Pharmaceuticals Corporation) - Combined Company Well-Funded to Generate Data from Multiple Phase 2 Studies - - Paul A. Friedman, M.D. Named Chairman and Chief Executive Officer of...
View ArticleDalCor Pharmaceuticals Completes $150 Million Financing (Caisse de dépôt et...
(Source: Caisse de dépôt et placement du Québec) -- Proceeds to Fund Phase 3 Trial of Dalcetrapib in Genetically Distinct Patients with Acute Coronary Syndrome (ACS) -- LONDON, April 19, 2016 -- DalCor...
View ArticleKaryopharm Presents Data Demonstrating the Potential of Nuclear Export...
(Source: Karyopharm Therapeutics Inc) NEWTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced preclinical...
View ArticleNordic Nanovector ASA: Exercise of employee share options and increase of...
(Source: Nordic Nanovector ASA) Oslo, Norway, 21 April 2016 Participants in Nordic Nanovector ASA's (the 'Company') (OSE: NANO) first share option program from 2011/2012 have on 20 April 2016 exercised...
View ArticleRexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the...
(Source: Rexahn Pharmaceuticals Inc) Data Featured at Late Breaking and Clinical Trials Session Suggest Potential Dose and Time Dependent Clinical Benefit of Archexinin Combination with Everolimus...
View Article